Cardiovascular Events with Finerenone in CKD and Diabetes

To the Editor: In their article on the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial, Pitt et al. (Dec. 9 issue) 1 report that patients who were treated with finerenone had a lower incidence of hospitalization for heart failure (one of the components of the primary composite outcome) than those who received placebo. However, additional issues should be considered. First, the data that were provided regarding baseline medications did not include the number and percentage of patients who were taking beta-blockers, which are used as therapy for heart failure and also may lower the risk . . .